Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Zhejiang Hisun Pharmaceutical Co's total inventories for the quarter that ended in Mar. 2026 was ¥1,356 Mil. Zhejiang Hisun Pharmaceutical Co's average total inventories from the quarter that ended in Dec. 2025 to the quarter that ended in Mar. 2026 was ¥1,521 Mil.
In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Zhejiang Hisun Pharmaceutical Co's Net-Net Working Capital per share for the quarter that ended in Mar. 2026 was ¥-1.48.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Zhejiang Hisun Pharmaceutical Co's Days Inventory for the
three
months ended in Mar. 2026 was 118.19.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Zhejiang Hisun Pharmaceutical Co's Inventory Turnover for the quarter that ended in Mar. 2026 was 0.77.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Zhejiang Hisun Pharmaceutical Co's Inventory-to-Revenue for the quarter that ended in Mar. 2026 was 0.64.
Zhejiang Hisun Pharmaceutical Co (SHSE:600267) Total Inventories Explanation
Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.
1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.
Zhejiang Hisun Pharmaceutical Co's Net-Net Working Capital Per Share for the quarter that ended in Mar. 2026 is
4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Zhejiang Hisun Pharmaceutical Co's Inventory to Revenue for the quarter that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.
When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.
Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.
Zhejiang Hisun Pharmaceutical Co Total Inventories Related Terms
Zhejiang Hisun Pharmaceutical Co Total Inventories Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zhejiang Hisun Pharmaceutical Co Total Inventories Chart
Zhejiang Hisun Pharmaceutical Co Total Inventories Calculation
Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.
Zhejiang Hisun Pharmaceutical Co (SHSE:600267) has a Total Inventories of ¥1,356 Mil as of Mar. 2026. The total amount of inventory as recorded on a company's balance sheet. View historical data for Zhejiang Hisun Pharmaceutical Co and its competitors.
Is Zhejiang Hisun Pharmaceutical Co's Total Inventories too high?
Zhejiang Hisun Pharmaceutical Co's current Total Inventories is ¥1,356 Mil. Overall, Zhejiang Hisun Pharmaceutical Co has a GF Score™ of 58/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Zhejiang Hisun Pharmaceutical Co's Total Inventories compare to ZTS?
Zhejiang Hisun Pharmaceutical Co's Total Inventories of ¥1,356 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Inventories for a Drug Manufacturers company?
A good Total Inventories depends on the Drug Manufacturers industry context. However, Total Inventories should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Inventories mean?
A high Total Inventories can signal that a stock is expensive relative to its fundamentals. The total amount of inventory as recorded on a company's balance sheet. View historical data for Zhejiang Hisun Pharmaceutical Co and its competitors. Zhejiang Hisun Pharmaceutical Co's current Total Inventories is ¥1,356 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zhejiang Hisun Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Zhejiang Hisun Pharmaceutical Co (SHSE:600267) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥8.85, compared to a current price of ¥11.72 — trading 32.4% above its estimated fair value. The current Total Inventories is ¥1,356 Mil. Zhejiang Hisun Pharmaceutical Co's overall GF Score™ is 58/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Inventories calculated?
Total Inventories is calculated from a company's financial statements. For Zhejiang Hisun Pharmaceutical Co (SHSE:600267), the current Total Inventories is ¥1,356 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zhejiang Hisun Pharmaceutical Co (SHSE:600267) Overvalued in 2026?
Based on GuruFocus' analysis, Zhejiang Hisun Pharmaceutical Co stock appears to be overvalued.
The current stock price of ¥11.72 is trading 32.4% above its estimated GF Value™ of ¥8.85.
GuruFocus considers Zhejiang Hisun Pharmaceutical Co to be Significantly Overvalued.
Key valuation signals for SHSE:600267:
Total Inventories: ¥1,356 Mil
GF Value™: ¥8.85 vs. price of ¥11.72 (32.4% above fair value)
No single metric tells the full story. See the SHSE:600267 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zhejiang Hisun Pharmaceutical Co Business Description
Zhejiang Hisun Pharmaceutical Co Ltd is a China-based pharmaceutical company. It is focused on the research, development, and distribution of pharmaceuticals. It produces and supplies antibiotics and anticancer drugs. The company's research channels cover indications like anticancer, cardiovascular, anti-infective, anti-parasitic, immunosuppressant and others. Its product portfolio includes active pharmaceutical ingredients like Anastrozole, Docetaxel, Methotrexate, and others and finished dosages such as letrozole tablets, anastrozole tablets, injection mitomycin, and others.
58GF Score
Get the complete analysis for SHSE:600267
Total Inventories is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600267 has been successfully added to your 
